Pethani Kaushik H, Borate Samruddhi J
Director, The Facial Surgery Hospital, Rajkot, Gujarat India.
The Facial Surgery Hospital, Rajkot, Gujarat India.
J Maxillofac Oral Surg. 2024 Oct;23(5):1267-1274. doi: 10.1007/s12663-023-02096-y. Epub 2024 Jan 20.
To evaluate the efficacy of a new drug combination in the medical management of oral submucous fibrosis (OSMF) patients.
This retrospective cohort study included 89 patients who were clinically diagnosed of having OSMF (grade I, II, III). These patients had been administered the new drug combination for 6 months and clinical parameters such as burning sensation score, mouth opening and tongue protrusion were evaluated at 1 month, 3 months, 6 months and 12 months post-medication retrospectively.
Out of the total 89 patients included in the study, 18 patients had Grade-I, 50 patients had Grade-II and 21 patients had Grade-III OSMF. A significant improvement was observed in the mouth opening and tongue protrusion in all the three grades of OSMF from baseline to 1 month, 3 months, 6 months and 12 months after treatment ( < 0.0001) on intra- and intergroup comparison. A significant reduction in the burning sensation score from baseline to 1 month, 3 months, 6 months and 12 months after treatment was observed ( < 0.0001) in all the three grades on intra group comparison.
This retrospective study showed that this novel drug combination is significantly effective in improving burning sensation score, mouth opening and tongue protrusion in OSMF grade I, II and III patients with results consistent after 1 year of follow-up.
评估一种新药组合用于口腔黏膜下纤维化（OSMF）患者药物治疗的疗效。
这项回顾性队列研究纳入了89例临床诊断为OSMF（I级、II级、III级）的患者。这些患者接受了该新药组合治疗6个月，并在用药后1个月、3个月、6个月和12个月时回顾性评估了诸如烧灼感评分、开口度和舌突出度等临床参数。
在纳入研究的89例患者中，18例为I级，50例为II级，21例为III级OSMF。组内和组间比较显示，从基线到治疗后1个月、3个月、6个月和12个月，所有三个等级的OSMF患者的开口度和舌突出度均有显著改善（<0.0001）。组内比较显示，所有三个等级的患者从基线到治疗后1个月、3个月、6个月和12个月，烧灼感评分均显著降低（<0.0001）。
这项回顾性研究表明，这种新型药物组合在改善I级、II级和III级OSMF患者的烧灼感评分、开口度和舌突出度方面具有显著疗效，随访1年后结果一致。
